On November 8, 2026, Lantheus Holdings, Inc. entered into a definitive agreement to sell its CDMO business and Springfield, New Jersey manufacturing facility to PharmaLogic, subject to customary closing conditions. Agilera will also manufacture lutetium Lu 177 dotatate for the company.
LNTH · Lantheus Holdings, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Curium US Holdings LLC will acquire Lantheus for $102.50 per share in cash, plus a contingent value right worth up to $12.00 per share upon commercial milestones; closing is expected in the first half of 2027.
Lantheus reported third-quarter revenue of $389.9 million, up 1.5%, while adjusted diluted EPS rose to $1.68. Its pending Curium merger is valued at up to approximately $8.0 billion, and full year 2026 guidance was suspended.
On October 21, 2026, the Federal Trade Commission issued Second Requests for Lantheus Holdings, Inc.’s merger, extending the HSR Act waiting period until 30 days after substantial compliance unless ended sooner; consummation remains expected in the first half of 2027.
On October 14, 2026, Lantheus stockholders approved the August 3, 2026 merger agreement and advisory compensation for named executive officers; the approved adjournment proposal was unnecessary because sufficient votes were cast.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted net income non-GAAP | 200.75M | Six Months Ended June 30 | — |
| Adjusted net income per share - diluted non-GAAP | $3.02 | Six Months Ended June 30 | — |
| Adjusted net income, as a percentage of revenues non-GAAP | 26.2% | Six Months Ended June 30 | — |
| Adjusted operating income non-GAAP | 271.16M | Six Months Ended June 30 | — |
| Adjusted operating income, as a percentage of revenues non-GAAP | 35.4% | Six Months Ended June 30 | — |
| Free cash flow non-GAAP | 211.77M | Six Months Ended June 30 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LNTH
this stock
Lantheus Holdings, Inc.
|
$6.67B | +53.3% | +3.6% | 24.9 | 5.6% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$67.96B | +36.4% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$51.90B | +7.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$49.28B | +35.3% | +4.3% | 96.0 | 2.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
$40.66B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 10, 2026
- This year
- 32
On November 8, 2026, Lantheus Holdings, Inc. entered into a definitive agreement to sell its CDMO business and Springfield, New Jersey manufacturing facility to PharmaLogic, subject to customary closing conditions. Agilera will also manufacture lutetium Lu 177 dotatate for the company.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LNTH | +0.4% | +1.8% | +2.7% | +1.5% | +53.3% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | +4.3% | +7.3% | +6.2% | +4.9% | +46.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.